The Filing Desk

Arbutus Biopharma vs uniQure

Arbutus Biopharma ABUS · uniQure QURE · Biotechnology

uniQure reported revenue of $16 million in fiscal 2025, about the same as Arbutus Biopharma's $14 million in fiscal 2025. Arbutus Biopharma's revenue grew 128.2% in its latest year, and uniQure's fell 40.6%. Arbutus Biopharma had an operating margin of -271.0%, against -1151.4% at uniQure. Free cash flow was −$40 million at Arbutus Biopharma and −$178 million at uniQure.

Side by side

Arbutus BiopharmauniQure
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$14M$16M
Revenue growth128.2%−40.6%
Revenue growth a year, last 5 years15.4%−15.6%
Gross margin—89.5%
Operating margin−271.0%−1,151.4%
Net margin−237.9%−1,236.0%
Free cash flow−$40M−$178M
Free cash flow margin−281.4%−1,108.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.2%18.2%
Last close$4.07$20.23
P/E at the last close3.6×—
Insider trades, last 12 months—sold $19.8 million
Piotroski F-score3 of 82 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arbutus BiopharmauniQure
Operating margin
Percent of revenue
Arbutus BiopharmauniQure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arbutus BiopharmauniQure

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arbutus Biopharma and uniQure pages.